Coeptis Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COEP Over the counter 2834 https://coeptistx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coeptis Therapeutics Inc

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors - May 17th, 2022 11:00 am
Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement - Apr 19th, 2022 11:00 am
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod - Apr 13th, 2022 8:05 pm
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma - Apr 13th, 2022 11:00 am
Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development - Jan 20th, 2022 1:00 pm
Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related Cancers - Aug 19th, 2021 12:30 pm